Edwards Lifesciences (NYSE:EW) Reaches New 52-Week High – Should You Buy?

Edwards Lifesciences Corporation (NYSE:EW)’s stock price reached a new 52-week high on Tuesday . The stock traded as high as $87.93 and last traded at $87.87, with a volume of 2539265 shares traded. The stock had previously closed at $85.78.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on EW. UBS Group reissued a “neutral” rating and issued a $94.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Evercore reissued an “outperform” rating and issued a $93.00 price target on shares of Edwards Lifesciences in a research note on Friday, April 24th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Monday, April 20th. Canaccord Genuity Group set a $85.00 price target on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, April 24th. Finally, Wells Fargo & Company raised their price target on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.65.

Edwards Lifesciences Stock Down 0.6%

The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The business’s 50 day simple moving average is $81.66 and its 200 day simple moving average is $82.98. The company has a market capitalization of $49.50 billion, a PE ratio of 45.73, a P/E/G ratio of 2.17 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The company had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. During the same period in the previous year, the firm earned $0.64 earnings per share. Edwards Lifesciences’s quarterly revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 620 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $81.14, for a total value of $50,306.80. Following the sale, the vice president directly owned 40,411 shares of the company’s stock, valued at approximately $3,278,948.54. The trade was a 1.51% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the completion of the sale, the chief financial officer directly owned 39,699 shares in the company, valued at $3,177,507.96. This trade represents a 24.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 105,829 shares of company stock valued at $8,799,770. 0.31% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Edwards Lifesciences

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Groupama Asset Managment purchased a new stake in shares of Edwards Lifesciences in the 1st quarter valued at approximately $1,337,000. Segall Bryant & Hamill LLC purchased a new stake in shares of Edwards Lifesciences in the 1st quarter valued at approximately $1,711,000. CTC Alternative Strategies Ltd. purchased a new stake in shares of Edwards Lifesciences in the 1st quarter valued at approximately $328,000. Vestor Capital LLC raised its stake in shares of Edwards Lifesciences by 55.2% in the 1st quarter. Vestor Capital LLC now owns 2,940 shares of the medical research company’s stock valued at $235,000 after acquiring an additional 1,046 shares during the period. Finally, J. Derek Lewis & Associates Inc. raised its stake in shares of Edwards Lifesciences by 145.1% in the 1st quarter. J. Derek Lewis & Associates Inc. now owns 9,290 shares of the medical research company’s stock valued at $744,000 after acquiring an additional 5,499 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.